Royalty Pharma plc (RPRX)

28,12 +0,12 (+0,43%) Alla chiusura: 04:00PM EDT

Royalty Pharma plc

110 East 59th Street
New York, NY 10022
United States
212 883 0200
https://www.royaltypharma.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Pablo Gerardo Legorreta	Founder, Chairman of the Board & CEO	N/D	N/D	1965
Mr. Terrance P. Coyne	Executive VP & CFO	4,56M	N/D	N/D
Mr. George Wingate Lloyd	Executive VP of Investments & Chief Legal Officer	4,56M	N/D	1960
Mr. Christopher Hite	Vice Chairman & Executive VP	4,56M	N/D	1968
Dr. Marshall Jonathan Urist M.D., Ph.D.	Executive Vice President of Research & Investments	4,56M	N/D	1976
Mr. Arthur Richard McGivern J.D.	Executive Vice President of Investments & General Counsel	N/D	N/D	N/D
Mr. Ashwin Pai M.D.	Executive Vice President of Investments	N/D	N/D	N/D
Ms. Kristin Stafford	Senior VP & Chief Accounting Officer	N/D	N/D	1982
Mr. Eric Cornelius Schneider	Senior VP & Chief Technology Officer	N/D	N/D	N/D
Dr. James Folmar Reddoch Ph.D.	Executive VP of Investments & Chief Scientific Officer	3,4M	N/D	1970

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Governance aziendale

L'ISS Governance QualityScore di Royalty Pharma plc al 1 aprile 2024 è 5. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 5; diritti degli azionisti: 6; retribuzione: 3.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.